A study in the Journal of Investigative Dermatology suggested that using a cannabinoid receptor type 2 (CB2) agonist called lenabasum may lessen the discomfort caused by amyopathic dermatomyositis. Dermatomyositis is a rare systemic autoimmune disease with distinctive cutaneous features frequently accompanied by muscle inflammation, interstitial lung disease, and malignancy. This phase 2 trial examined the potential benefits of activating the endocannabinoid system to reduce the inflammation causing the symptoms.

Study participants included twenty-two adults diagnosed with moderate to severe skin disease caused by dermatomyositis. They received 20 mg daily of lenabasum or a placebo for 28 days, then 20 mg twice daily for 56 days. Their Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) levels were evaluated relative to baseline as well as secondary outcomes such as quality of life (measured with the Skindex-29) and specific biomarkers.

More than 40% of the patients taking lenabasum demonstrated significant improvements. The study showed that the CB2 agonist lenabasum improved the skin of amyopathic dermatomyositis patients. The researchers noted that lenabasum was well-tolerated and effective. More than 40% of the patients in the study taking lenabasum demonstrated significant improvements on the CDASI, a validated disease-severity scale. Results showed a trend for the change from baseline CDASI to be greater in lenabasum versus placebo starting at Day 43, two weeks after a dose increase. On Day 113 there was a statistically significant difference between the two groups. The researchers noted that the drug was well tolerated.

Research investigates whether the severity of SARS-CoV-2 infection can be predicted by analyzing the immunophenotype in the blood of cardiovascular disease (CVD) patients.

While Wilms tumor—also known as nephroblastoma—is rare, it is the most prevalent childhood kidney cancer. Researchers at Children’s Hospital Los Angeles have now pinpointed a disruption in early kidney progenitor cell development that can be linked to the formation of Wilms tumor.

In a study published in Advanced Science, researchers at the GOFARR Laboratory in Urology compared kidney progenitor cells from a tumor with precursor cells from a healthy kidney. Normally, these precursor cells mature into kidney cells, but when their early development is dysregulated, they behave like cancer stem cells.

While most children with Wilms tumor are successfully treated, current therapies are aggressive. A minority of these patients have unfavorable prognoses or relapses; for these children, there is no existing therapy. “By achieving a more precise understanding of how Wilms tumors develop, our goal is to find new treatments for all types of Wilms tumor,” says Laura Perin, Ph.D., Co-Director of the GOFARR laboratory and senior study co-author with Stefano Da Sacco, Ph.D., another researcher at the GOFARR Laboratory.

Multiple people were killed and more than 30 others injured in large crashes involving up to 90 vehicles on Interstate 55 in south-central Illinois during a dust storm, authorities said Monday afternoon.

According to Illinois State Police, multiple fatalities were reported with the crashes, but an exact number remained unclear. At least 30 others, ranging in age from 2 to 80 years old, were taken to area hospitals. Their conditions weren’t immediately known.

Authorities said they were still conducting additional searches through the vehicles involved, which included an estimated 30 commercial vehicles and 40 to 60 passenger cars. The biggest challenge, according to Illinois State Police Major Ryan Starric, the biggest challenge was trying to get to victims quickly.